Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
A new greenfield facility for Merck Sharp & Dohme is the sharpest detail in an otherwise routine earnings recap.
— 7 earlier stories on Aurobindo Pharma Ltd. →What's new
- TheraNym signed an additional schedule with MSD to build a greenfield drug substance facility.
- The facility's estimated capital expenditure is US$150-175 million.
- CuraTeQ completed Phase 3 for Omalizumab and will file Denosumab with the EMA by Q2 2026.
Why this matters
A greenfield build for a single client is a concrete capital bet, not a speculative pipeline slide. It deepens a committed partnership with one of the world's largest drug makers and anchors the biologics subsidiary with a physical asset.
What we're watching
- Details on the financing mix and construction timeline for the US$150-175M plant.
- The EMA filing decision for Denosumab by Q2 2026.
- Execution against the target of 15 biosimilars in a US$50B market by 2030.
The full read
Aurobindo's Q4 presentation was a recap of known results. Revenue of ₹8,853 crore was up 5.6%, net profit of ₹921 crore was up 2%. The new detail is a US$150-175 million capex commitment through biosimilars subsidiary TheraNym. The company will build a greenfield drug substance plant for MSD. Separately, CuraTeQ completed Phase 3 for Omalizumab and is targeting a Q2 2026 EMA filing for Denosumab. Aurobindo now has 15 biosimilars in development, aiming at what it calls a US$50 billion addressable market by 2030. The plant deal is the material update. It commits a large sum to a single client relationship. Routine earnings. One new plant.
Questions answered
- What is the new agreement between TheraNym and MSD?
- TheraNym signed an additional product schedule with MSD to build a new, greenfield drug substance facility. The deal expands an existing partnership with a dedicated manufacturing plant.
- How large is the capital commitment?
- The facility is estimated to cost US$150-175 million. The presentation did not disclose the specific funding source or project timeline.
- What did the earnings presentation say about Aurobindo's core results?
- Q4 revenue was ₹8,853 crore, up 5.6% year-on-year, and net profit was ₹921 crore, up 2%. These figures were already disclosed on May 13, 2026.
- What progress was reported on the biosimilars pipeline?
- CuraTeQ successfully completed Phase 3 for Omalizumab and plans to file Denosumab with the European Medicines Agency by Q2 2026.
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AUROPHARMA →- 21 May 2026 · 8:49 PM IST Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
- 7d ago Aurobindo's biosimilars arm clears Brazil's ANVISA for Hyderabad plant
- 39d ago Aurobindo gets FTC nod for Lannett, moves closing to June
- 46d ago Aurobindo gets second OAI plant in six months
- 67d ago Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year